Cell Impact : rights issue is oversubscribed

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN CELL IMPACT AB (PUBL). SEE ALSO THE SECTION "IMPORTANT INFORMATION" BELOW IN THIS DOCUMENT.

The Board of Directors in Cell Impact resolved on November 29, 2021 pursuant to the authorization granted by the extra general meeting on November 16, 2021, on a fully guaranteed Rights Issue of up to approximately SEK 349 million.

Preliminary outcome

The preliminary outcome indicates that approximately 15.8 million series B shares, corresponding to approximately 94 percent of the offered series B shares, have been subscribed for with subscription rights in the Rights Issue. Additionally, applications for subscription of approximately 12.0 million series B shares without subscription rights, corresponding to approximately 71 percent of the offered series B shares, have been received. Thus, the preliminary outcome indicates that the Rights Issue is oversubscribed and that no guarantee commitments will be utilized.

Notice of allotment

Those who have subscribed for series B shares without subscription rights will be allocated series B shares in accordance with the principles set out in the prospectus published on December 6, 2021. Notice of allotment to the persons who subscribed for series B shares without subscription rights is expected to be distributed on December 28, 2021. Subscribed and allotted series B shares shall be paid in cash within two banking days in accordance with the instructions on the settlement note sent to the subscriber. Subscribers who have subscribed through a nominee will receive notification of allocation in accordance with their respective nominee's procedures. Only those who have been allotted shares will be notified.

Final outcome

The final outcome of the Rights Issue is expected to be published around December 27, 2021. The last day of trading in paid subscribed shares (BTAs) is expected to be on January 4, 2022. The new series B shares subscribed for with and without subscription rights are expected to be traded on Nasdaq First North Growth Market as from January 11, 2022.

Advisers

In conjunction with the Rights Issue, the Company has engaged Carnegie Investment Bank AB (publ) as Sole Global Coordinator and Joint Bookrunner and Bryan, Garnier & Co as Joint Bookrunner. Advokatfirman Vinge and Advokatfirman Wåhlin AB act as legal advisers.

This information is information that Cell Impact AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation.